|

Feasibility and Acceptability of HCV Treatment in Pregnancy

RECRUITINGSponsored by Washington University School of Medicine
Actively Recruiting
SponsorWashington University School of Medicine
Started2024-02-01
Est. completion2026-02-28
Eligibility
Age18 Years+
SexFEMALE
Locations2 sites
View on ClinicalTrials.gov →

NCT06367465

Summary

Pregnant adults over the age of 18 who are seen in the Washington University obstetrics and gynecology, maternal fetal medicine or infectious diseases clinic or admitted to BJH with hepatitis C virus infection who have a history of past or current drug use Participant Duration: Approximately 1 year. Aims: Aim 1 - Evaluate adherence and treatment completion rates when glecaprevir-pibrentasvir is started during pregnancy for women who use drugs. Aim 2 - Evaluate patient experience with hepatitis C virus treatment during pregnancy.

Eligibility

Age: 18 Years+Sex: FEMALE
Inclusion Criteria:

* Female patients ≥ 18 years old, pregnant at the time of study intake, diagnosed with hepatitis c virus infection and a history of past or current drug use.

Exclusion Criteria:

\-

Conditions3

Hepatitis CLiver DiseasePregnancy Complications

Locations2 sites

Barnes Jewish Hospital
St Louis, Missouri, 63110
Tracey Bach314-273-6075habrockt@wustl.edu
Washington Univeristy
St Louis, Missouri, 63110
Laura Marks, MD,PhDmarks@wustl.edu

Browse More Trials

Liver Disease trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.